Alexander J Blood, Lee-Shing Chang, Caitlin Colling, Gretchen Stern, Daniel Gabovitch, Guinevere Feldman, Asma Adan, Fanta Waterman, Emily Durden, Carol Hamersky, Joshua Noone, Samuel J Aronson, Paul Liberatore, Thomas A Gaziano, Lina S Matta, Jorge Plutzky, Christopher P Cannon, Deborah J Wexler, Benjamin M Scirica
AIM: Describe the rationale for and design of Diabetes Remote Intervention to improVe use of Evidence-based medications (DRIVE), a remote medication management program designed to initiate and titrate guideline-directed medical therapy (GDMT) in patients with type 2 diabetes (T2D) at elevated cardiovascular (CV) and/or kidney risk by leveraging non-physician providers. METHODS: An electronic health record based algorithm is used to identify patients with T2D and either established atherosclerotic CV disease (ASCVD), high risk for ASCVD, chronic kidney disease, and/or heart failure within our health system...
January 31, 2024: Primary Care Diabetes